Hemispherx Biopharma Inc., of Philadelphia, said authors of a peer-reviewed article published in Clinical and Cellular Immunology observed that Ampligen, a Toll-like receptor 3 (TLR3) agonist, unlike all other Toll-like receptors studied to date, has a mechanism of action making it potentially adaptable as a treatment for disorders such as multiple sclerosis (MS).